

Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B

George V. Papatheodoridis, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Margarita Papatheodoridi, Nikolaos Gatselis, Rhea Veelken, Marta Lopez-Gomez, Bettina E Hansen, Savvoula Savvidou, Anastasia Kourikou, John Vlachogiannakos, Kostas Galanis, Cihan Yurdaydin, Rafael Esteban, Harry LA Janssen, Thomas Berg, Pietro Lampertico.

Table of contents

Table S1.....	2
Supplementary references.....	4

Table S1. Formulas and cut-off values of risk scores developed for prediction of hepatocellular carcinoma (HCC) in treated chronic hepatitis B patients.

Risk score	Formula of HCC risk score	Low-risk cut-off	High-risk cut-off
PAGE-B ¹	Age (16-29/30-39/40-49/50-59/60-69/≥70 years: 0/2/4/6/8/10) + Sex (M/F:6/0) + Platelets (≥200/100-199/<100 x10 ³ /mm ³ : 0/6/9)	10	18
HCC-RESCUE ²	Age (years) +15 × Sex (M/F:1/0) +23 × Cirrhosis (Yes/No:1/0)	65	85
CAMD ³	Age (<40/40-49/50-59/≥60 years:0/5/8/10) + Sex (M/F:2/0) + Diabetes (Yes/No:1/0) + Cirrhosis (No/ Yes, with age <40 years /Yes, with age ≥40 years:0/10/6)	8	14
mPAGE-B ⁴	Age (16-29/30-39/40-49/50-59/60-69/≥70 years: 0/3/5/7/9/11) +Sex (M/F:2/0) + Platelets (≥250/200-250/150-200/100-150/<100 x10 ³ /mm ³ :0/2/3/4/5) + Albumin (≥4/3.5-4/3-3.5/<3 g/dL:0/2/3/4)	9	13
AASL ⁵	Age (<30/30-39/40-49/50-59/60-69/≥70 years: 0/2/4/6/8/10) + Albumin (≥3.5/2.8-3.4/<2.8 g/dl: 0/3/5) + Sex (M/F:3/0) + Cirrhosis (No/Yes: 0/11)	6	20
CAGE-B ⁶	Age at year 5 (23-29/30-39/40-49/50-59/60-69/≥70 years: 0/2/4/6/8/10) + Cirrhosis at	6	11

	baseline & LSM at year 5 (No cirrhosis & LSM<12 kPa/ Cirrhosis & LSM<12 kPa/ Cirrhosis & LSM≥12 kPa: 0/3/6)		
SAGE-B ⁶	Age at year 5 (23-29/30-39/40-49/50-59/60-69/≥70 years: 0/2/4/6/8/10) + LSM at year 5 (<12 kPa/≥12 kPa:0/5)	6	11

M/F: male/female, LSM: liver stiffness measurement.

Supplementary references

1. Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. *J Hepatol* 2016;64:800-806.
2. Sohn W, Cho JY, Kim JH, Lee JI, Kim HJ, Woo MA et al. Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B. *Clin Mol Hepatol* 2017;23:170-178.
3. Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. *J Hepatol* 2018;69:278-285.
4. Kim JH, Kim YD, Lee M, Jun BG, Kim TS, Suk KT et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. *J Hepatol* 2018;69:1066-1073.
5. Yu JH, Suh YJ, Jin YJ, Heo NY, Jang JW, You CR et al. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir. *Eur J Gastroenterol Hepatol* 2019;31:865-872.
6. Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van BF, Buti M et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. *J Hepatol* 2020;72:1088-1096.